UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 90

Sortiert nach

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Cancer discovery, 2020-08, Vol.10 (8), p.1194-1209

2020

Volltextzugriff (PDF)

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Nature communications, 2019-04, Vol.10 (1), p.1772-1772, Article 1772

2019

Volltextzugriff (PDF)

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Molecular cancer therapeutics, 2017-06, Vol.16 (6), p.1010-1020

2017

Volltextzugriff (PDF)

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (13), p.3942-3953

2016

Volltextzugriff (PDF)

Drug discovery approaches to target Wnt signaling in cancer stem cells

Oncotarget, 2010-11, Vol.1 (7), p.563-577

2010

Volltextzugriff (PDF)

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Cancer immunology research, 2019-09, Vol.7 (9), p.1457-1471

2019

Volltextzugriff (PDF)

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Cell, 2018-01, Vol.172 (3), p.578-589.e17

2018

Volltextzugriff (PDF)

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Molecular cancer therapeutics, 2020-10, Vol.19 (10), p.2044-2056

2020

Volltextzugriff (PDF)

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

JTO clinical and research reports, 2021-02, Vol.2 (2), p.100103-100103, Article 100103

2021

Volltextzugriff (PDF)

Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.1-8

2020

Volltextzugriff (PDF)

Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)

Bioorganic & medicinal chemistry letters, 2009-06, Vol.19 (11), p.2924-2927

2009

Volltextzugriff (PDF)

Deregulation and Mislocalization of the Cytokinesis Regulator ECT2 Activate the Rho Signaling Pathways Leading to Malignant Transformation

The Journal of biological chemistry, 2004-02, Vol.279 (8), p.7169-7179

2004

Volltextzugriff (PDF)

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models

Cancer chemotherapy and pharmacology, 2022-04, Vol.89 (4), p.515-527

2022

Volltextzugriff (PDF)

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1717-1726

2017

Volltextzugriff (PDF)

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells

Oncotarget, 2014-09, Vol.5 (18), p.8637-8650

2014

Volltextzugriff (PDF)

Selective retinoids and rexinoids in cancer therapy and chemoprevention

Drug Discovery Today, 2002-12, Vol.7 (23), p.1165-1174

2002

Volltextzugriff (PDF)

Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers

Journal of translational medicine, 2013-08, Vol.11 (1), p.198-198, Article 198

2013

Volltextzugriff (PDF)

Rho exchange factor ECT2 is induced by growth factors and regulates cytokinesis through the N-terminal cell cycle regulator-related domains

Journal of cellular biochemistry, 2003-11, Vol.90 (4), p.819-836

2003

Volltextzugriff (PDF)

9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors

Bioorganic & medicinal chemistry letters, 2015-07, Vol.25 (14), p.2809-2812

2015

Volltextzugriff (PDF)

Benzo[ d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)—Hit to Lead studies

Bioorganic & medicinal chemistry letters, 2009-09, Vol.19 (17), p.5063-5066

2009

Volltextzugriff (PDF)

Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5‑d]pyrrolo[2,3‑b]pyridine Inhibitors

ACS medicinal chemistry letters, 2015-08, Vol.6 (8), p.845-849

2015

Volltextzugriff (PDF)

Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics

Molecular cancer therapeutics, 2006-06, Vol.5 (6), p.1571-1576

2006

Volltextzugriff (PDF)

Correction: Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and Histologic characteristics of human cancers

Journal of translational medicine, 2014-03, Vol.12 (1), p.67-67

2014

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(87)

Publikationsform

Artikel
(88)
Buchkapitel
(2)

Sprache

Englisch
(90)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(50)
Humans
(33)
Animals
(28)
Oncology
(23)
Biological And Medical Sciences
(21)
Mice
(20)
Cell Biology
(17)
Fundamental And Applied Biological Sciences. Psychology
(15)
Biochemistry & Molecular Biology
(14)
Molecular Sequence Data
(14)
Genetics & Heredity
(13)
Female
(11)
Male
(11)
Pharmacology & Pharmacy
(11)
Amino Acid Sequence
(10)
Phosphorylation
(10)
Chemistry, Medicinal
(9)
Molecular And Cellular Biology
(9)
3t3 Cells
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors

Drug discovery approaches to target Wnt signaling in cancer stem cells

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy

Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Deregulation and Mislocalization of the Cytokinesis Regulator ECT2 Activate the Rho Signaling Pathways Leading to Malignant Transformation

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells

Selective retinoids and rexinoids in cancer therapy and chemoprevention

Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers

Rho exchange factor ECT2 is induced by growth factors and regulates cytokinesis through the N-terminal cell cycle regulator-related domains

9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors

Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms

Benzo[ d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)—Hit to Lead studies

Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5‑d]pyrrolo[2,3‑b]pyridine Inhibitors

Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics

Correction: Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and Histologic characteristics of human cancers

Suchergebnisse filtern